| Ryan Ashley Greene, MD | |
|
4700 S Washington St Ste G, Grand Forks, ND 58201-8155 | |
| (701) 205-3000 | |
| (701) 732-2501 |
| Full Name | Ryan Ashley Greene |
|---|---|
| Gender | Female |
| Speciality | Psychiatry |
| Experience | 10 Years |
| Location | 4700 S Washington St Ste G, Grand Forks, North Dakota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104231505 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 71037 (Minnesota) | Secondary |
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 14924 (North Dakota) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Peterson Medical Clinics Llc | 9335412220 | 48 |
| Astera Health | 2961395272 | 94 |
| Peterson Medical Clinics Llc | 9335412220 | 48 |
| Yukon-kuskokwim Health Corporation | 5193718765 | 77 |
| Peterson Medical Clinics Llc | 9335412220 | 48 |
| Peterson Medical Clinics Llc | 9335412220 | 48 |
News Archive
Eighteen years later, people who worked with lead have significant loss of brain cells and damage to brain tissue, according to a new study published in the May 23, 2006, issue of Neurology, the scientific journal of the American Academy of Neurology.
More prostate cancers were detected among men who were screened every two years than men screened every four years, according to a study published online August 28 in the Journal of the National Cancer Institute.
It is unlikely that different types of depression can be combined to one single disease called Major Depression. When testing the efficacy of antidepressants or psychotherapy, clinicians should make an attempt to specify the subtypes of depression and to combine antidepressants and psychotherapy in a sequential approach.
Sunovion Pharmaceuticals Inc. today announced the results of the PEARL 3 study, the third phase 3 worldwide clinical trial of Latuda® (lurasidone HCl) tablets, a once-daily atypical antipsychotic agent recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with schizophrenia. In this six-week, placebo-controlled trial, both fixed doses of LATUDA 80 and 160 mg once-daily, demonstrated statistically significant improvement in symptoms of schizophrenia versus placebo across both primary and secondary efficacy measures.
Scientists engineered stem cells to better understand the mechanisms behind a form of leukemia caused by changes in a key gene, according to a study led by Mount Sinai researchers and published online today in the journal Cell Reports.
› Verified 4 days ago
| Entity Name | Psj Acquisition Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679709802 PECOS PAC ID: 7012062235 Enrollment ID: O20090918000240 |
News Archive
Eighteen years later, people who worked with lead have significant loss of brain cells and damage to brain tissue, according to a new study published in the May 23, 2006, issue of Neurology, the scientific journal of the American Academy of Neurology.
More prostate cancers were detected among men who were screened every two years than men screened every four years, according to a study published online August 28 in the Journal of the National Cancer Institute.
It is unlikely that different types of depression can be combined to one single disease called Major Depression. When testing the efficacy of antidepressants or psychotherapy, clinicians should make an attempt to specify the subtypes of depression and to combine antidepressants and psychotherapy in a sequential approach.
Sunovion Pharmaceuticals Inc. today announced the results of the PEARL 3 study, the third phase 3 worldwide clinical trial of Latuda® (lurasidone HCl) tablets, a once-daily atypical antipsychotic agent recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with schizophrenia. In this six-week, placebo-controlled trial, both fixed doses of LATUDA 80 and 160 mg once-daily, demonstrated statistically significant improvement in symptoms of schizophrenia versus placebo across both primary and secondary efficacy measures.
Scientists engineered stem cells to better understand the mechanisms behind a form of leukemia caused by changes in a key gene, according to a study led by Mount Sinai researchers and published online today in the journal Cell Reports.
› Verified 4 days ago
| Entity Name | Peterson Medical Clinics Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699295774 PECOS PAC ID: 9335412220 Enrollment ID: O20170828003640 |
News Archive
Eighteen years later, people who worked with lead have significant loss of brain cells and damage to brain tissue, according to a new study published in the May 23, 2006, issue of Neurology, the scientific journal of the American Academy of Neurology.
More prostate cancers were detected among men who were screened every two years than men screened every four years, according to a study published online August 28 in the Journal of the National Cancer Institute.
It is unlikely that different types of depression can be combined to one single disease called Major Depression. When testing the efficacy of antidepressants or psychotherapy, clinicians should make an attempt to specify the subtypes of depression and to combine antidepressants and psychotherapy in a sequential approach.
Sunovion Pharmaceuticals Inc. today announced the results of the PEARL 3 study, the third phase 3 worldwide clinical trial of Latuda® (lurasidone HCl) tablets, a once-daily atypical antipsychotic agent recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with schizophrenia. In this six-week, placebo-controlled trial, both fixed doses of LATUDA 80 and 160 mg once-daily, demonstrated statistically significant improvement in symptoms of schizophrenia versus placebo across both primary and secondary efficacy measures.
Scientists engineered stem cells to better understand the mechanisms behind a form of leukemia caused by changes in a key gene, according to a study led by Mount Sinai researchers and published online today in the journal Cell Reports.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ryan Ashley Greene, MD 4700 S Washington St Ste G, Grand Forks, ND 58201-8155 Ph: (701) 205-3000 | Ryan Ashley Greene, MD 4700 S Washington St Ste G, Grand Forks, ND 58201-8155 Ph: (701) 205-3000 |
News Archive
Eighteen years later, people who worked with lead have significant loss of brain cells and damage to brain tissue, according to a new study published in the May 23, 2006, issue of Neurology, the scientific journal of the American Academy of Neurology.
More prostate cancers were detected among men who were screened every two years than men screened every four years, according to a study published online August 28 in the Journal of the National Cancer Institute.
It is unlikely that different types of depression can be combined to one single disease called Major Depression. When testing the efficacy of antidepressants or psychotherapy, clinicians should make an attempt to specify the subtypes of depression and to combine antidepressants and psychotherapy in a sequential approach.
Sunovion Pharmaceuticals Inc. today announced the results of the PEARL 3 study, the third phase 3 worldwide clinical trial of Latuda® (lurasidone HCl) tablets, a once-daily atypical antipsychotic agent recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with schizophrenia. In this six-week, placebo-controlled trial, both fixed doses of LATUDA 80 and 160 mg once-daily, demonstrated statistically significant improvement in symptoms of schizophrenia versus placebo across both primary and secondary efficacy measures.
Scientists engineered stem cells to better understand the mechanisms behind a form of leukemia caused by changes in a key gene, according to a study led by Mount Sinai researchers and published online today in the journal Cell Reports.
› Verified 4 days ago
Dr. Matthew Joseph Roller, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1300 S Columbia Rd, Grand Forks, ND 58201 Phone: 701-780-2300 | |
Dr. William Benjamin Pryatel Jr., M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1200 S. Columbia Rd, Grand Forks, ND 58201 Phone: 701-780-5000 Fax: 701-253-3999 | |
Kathryn M. Tevington, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 151 S 4th St, Suite 401, Grand Forks, ND 58201 Phone: 701-795-3000 Fax: 701-795-3050 | |
Dr. Rose J. Julius, DO Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1200 S Columbia Rd - Altru Health System, Grand Forks, ND 58201 Phone: 701-780-5000 Fax: 701-780-3472 | |
Dr. Kenneth Chidi Asogwa, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 860 S Columbia Rd, Grand Forks, ND 58201 Phone: 701-780-6697 Fax: 701-780-1507 | |
Jinal Desai, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: Altru Health System, 1200 South Columbia Road, Grand Forks, ND 58201 Phone: 701-780-5000 Fax: 701-780-4477 |